Breaking News, Collaborations & Alliances

AbbVie, FutureGen Enter License Agreement to Develop FG-M701

Will advance the development of FG-M701 for the treatment of IBD.

Author Image

By: Charlie Sternberg

Associate Editor

AbbVie and FutureGen Biopharmaceutical Co., Ltd. have announced a license agreement to develop FG-M701, a next-generation TL1A antibody for the treatment of IBD currently in preclinical development.   FG-M701 is a fully human monoclonal antibody targeting TL1A, a clinically validated target in IBD. FG-M701 is uniquely engineered with potential best-in-class functional characteristics compared to first-generation TL1A antibodies, with the goal to drive greater efficacy and less frequent dosing ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters